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ABSTRACT
Introduction Proximal femoral (hip) fracture is common, 
serious and costly. Rehabilitation may improve functional 
recovery but evidence of effectiveness and cost- 
effectiveness are lacking. An enhanced rehabilitation 
intervention was previously developed and a feasibility 
study tested the methods used for this randomised 
controlled trial (RCT). The objectives are to compare the 
effectiveness and cost- effectiveness of the enhanced 
rehabilitation programme following surgical repair of 
proximal femoral fracture in older people compared with 
usual care.
Methods and analysis Protocol for phase III, parallel- 
group, two- armed, superiority, pragmatic RCT with 1:1 
allocation ratio; allocation sequence by minimisation 
programme with a built- in random element; secure web- 
based allocation concealment. The two treatments will 
be usual care (control) and usual care plus an enhanced 
rehabilitation programme (intervention). The enhanced 
rehabilitation will consist of a patient- held information 
workbook, goal setting diary and up to six additional therapy 
sessions. Outcome assessment and statistical analysis will 
be performed blind; patient and carer participants will be 
unblinded. Outcomes will be measured at baseline, 17 and 
52 weeks’ follow- up. Primary outcome at 52 weeks will be 
the Nottingham Extended Activities of Daily Living scale. 
Secondary outcomes will measure anxiety and depression, 
health utility, cognitive status, hip pain intensity, falls self- 
efficacy, fear of falling, grip strength and physical function. 
Carer strain, anxiety and depression will be measured 
in carers. All safety events will be recorded, and serious 
adverse events will be assessed to determine whether they 
are related to the intervention and expected. Concurrent 
economic evaluation will be a cost- utility analysis from 
a health service and personal social care perspective. 
An embedded process evaluation will determine the 
mechanisms and processes that explain the implementation 
and impacts of the enhanced rehabilitation programme.
Ethics and dissemination National Health Service 
research ethics approval reference 18/NE/0300. Results 
will be disseminated by peer- reviewed publication.
Trial registration number ISRCTN28376407; Pre- results 
registered on 23 November 2018.
INTRODUCTION
Proximal femoral fracture, more commonly 
referred to as hip fracture, is a common, 
major health problem in old age.1 It is 
projected to increase further as the popula-
tion ages.2 3 Mortality is high,4 5 and of those 
who survive to 1 year, 29% fail to regain their 
level of functioning, in terms of restrictions 
of activities of daily living6; many lose their 
independence. This imposes a large cost 
burden on society, estimated to be approx-
imately £2.3 billion a year in the UK.7 The 
majority of costs is incurred in the commu-
nity and social care setting in the 12 months 
Strengths and limitations of this study
 ► Pragmatic phase III randomised controlled trial fol-
lowing phase I intervention development and phase 
II feasibility study.
 ► Concurrent economic evaluation with a health ser-
vice and personal social care perspective.
 ► Embedded process evaluation to determine the 
mechanisms and processes that explain the imple-
mentation and impacts of the enhanced rehabilita-
tion programme.
 ► Only patients with mental capacity to consent are 
eligible, therefore excluding a large number of po-
tential participants lacking capacity.
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following hospital discharge, which are almost four times 
higher than the costs of the acute hospital admission.8 
Frail individuals are at particular risk of secondary future 
proximal femoral fracture, resulting in worse morbidity 
and mortality outcomes.9
The National Institute of Health and Clinical Excel-
lence (NICE) have issued guidelines for the manage-
ment of hip fracture.10 This includes the provision of a 
co- ordinated multidisciplinary rehabilitation programme 
starting in hospital during postoperative recovery and 
continuing in the community following discharge.10 
Where possible such rehabilitation programmes should 
consider individual patient goals, facilitate a return to 
prefracture independence and provide patients and 
carers with written information to support the rehabili-
tation programme and long- term outcomes. The Hip 
Sprint audit reported that community rehabilitation 
services were inconsistent.11
Rationale
There have been four relevant Cochrane systematic 
reviews with inconclusive results.12–15 These have exam-
ined different types and intensities of in- patient reha-
bilitation,12 mobilisation strategies,13 psychosocial 
functioning after hip fracture14 and rehabilitation for 
those with dementia following hip fracture surgery.15 
Other systematic reviews have reported improved walking 
ability,16 strength and physical function,17 including those 
with mild to moderate dementia.18 These systematic 
reviews concluded that while individual components of 
rehabilitation programmes may aid recovery after a hip 
fracture, there is insufficient evidence to demonstrate 
clinical effectiveness or cost- effectiveness of an overall 
care pathway, and that further research is required.
A previous study19 completed the first two phases of the 
Medical Research Council framework for complex inter-
ventions.20 The first phase developed an enhanced reha-
bilitation intervention which, in addition to usual care, 
included a patient- held workbook, a goal setting diary 
and up to six additional home- based therapy sessions.21 
The second phase of the study was a randomised feasi-
bility study, which assessed the acceptability of the new 
rehabilitation programme and the feasibility of trial 
methods for a definitive phase III randomised controlled 
trial (RCT).22 23 Although this feasibility study was under-
powered to assess effectiveness, the intervention showed a 
medium- sized improvement in the Nottingham Extended 
Activities of Daily Living (NEADL) scale compared 
with usual care (Cohen’s d 0.63). A process evaluation 
described the implementation of the rehabilitation 
programme and informed how to enhance recruitment 
and improve the intervention.24
Risk and benefits
The enhanced rehabilitation programme demonstrated 
a potential improvement in activities of daily living in the 
feasibility study. Possible risks of rehabilitation interven-
tions would include injury or falling when performing 
therapeutic exercises, which must be weighed against the 
risk to health of sedentary behaviour.
Primary objective
To determine the effectiveness of an enhanced rehabili-
tation programme following surgical repair of proximal 
femoral fracture in older people compared with usual 
care, in terms of the performance of activities of daily 
living at 52 weeks follow- up.
Secondary objectives
1. To compare the cost- effectiveness of an enhanced re-
habilitation programme following surgical repair of 
proximal femoral fracture in older people compared 
with usual care at 52 weeks follow- up.
2. To determine the effectiveness of an enhanced reha-
bilitation programme following surgical repair of prox-
imal femoral fracture in older people compared with 
usual care, in terms of the performance of activities of 
daily living at 17 weeks follow- up.
3. To determine the effectiveness of an enhanced reha-
bilitation package following surgical repair of proxi-
mal femoral fracture in older people compared with 
usual care, in terms of anxiety and depression at 17 
and 52 weeks follow- up.
4. To assess whether the enhanced rehabilitation inter-
vention creates change in self- efficacy, hip pain, cog-
nitive function, fear of falling and physical function 
as potential mediators for improving activities of daily 
living at 17 and 52 weeks follow- up.
5. To assess whether the enhanced rehabilitation inter-
vention creates change in strain, anxiety and depres-
sion in carers at 17 and 52 weeks follow- up.
6. To determine the mechanisms and processes that 
explain the implementation and impacts of the en-
hanced rehabilitation programme and whether there 
are adverse effects.
METHODS AND ANALYSIS
Trial design
This is a pragmatic, multisite, parallel- group, two- armed, 
superiority RCT with 1:1 allocation ratio and an internal 
pilot phase (figure 1). Outcome assessment and statistical 
analysis will be blinded; patient and carer participants and 
clinicians will be unblinded. A concurrent economic eval-
uation will be a cost- utility analysis from a health service 
and personal social care perspective. An embedded 
process evaluation will examine the mechanisms and 
processes that explain the implementation and impacts 
of the enhanced rehabilitation programme. The RCT was 
registered on 23 November 2018 . Trial registration data 
can be found in online supplemental appendix 1.
Trial setting and selection of sites/clinicians
Sites were recruited by coinvestigators in different regions 
of England and Wales with a spread of socioeconomic 
conditions and a mixture of rural and urban locations: 
Kent (CS), Merseyside (NW), Norwich (TOS), North 
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Wales (RL), Nottingham (PL) and South Wales (MB). 
The sites had to include trauma centres treating proximal 
femoral fracture and links to community rehabilitation 
teams, which could accommodate the extra community 
rehabilitation sessions.
Patients will be recruited on orthopaedic, rehabilitation 
and community hospital wards or after hospital discharge 
home. The intervention will be delivered in the commu-
nity, following hospital discharge, by community teams 
receiving referrals from the acute hospital sites and their 
associated community hospitals.
Selection of sites/clinicians
Sites have been opened to recruitment in Nottingham, 
Norfolk, North Wales, South Wales and East Kent. Further 
sites are planned in west Kent, Derby and Cheshire plus 
others. The site trial teams comprise principal investiga-
tors, hospital and community NHS staff, research assis-
tants and support staff from clinical research networks.
Trial population
Inclusion criteria
1. Age 60 years or older.
2. Recent proximal femoral fracture.
3. Surgical repair by replacement arthroplasty, hemiar-
throplasty or internal fixation.
4. Living in their own home prior to hip fracture.
5. Living and receiving rehabilitation from the NHS in 
the area covered by the trial sites.
Figure 1 Participant flowchart for Fracturein the Elderly Multidisciplinary Rehabilitation—phase III (FEMuR III).
 o
n
 O
ctober 21, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-039791 on 16 October 2020. Downloaded from 
4 Williams N, et al. BMJ Open 2020;10:e039791. doi:10.1136/bmjopen-2020-039791
Open access 
Exclusion criteria
1. Living in residential or nursing homes prior to hip 
fracture.
2. Participants unable to understand English or Welsh.
3. Lacking mental capacity to give informed consent.
Carer participants
We will also recruit carer participants to evaluate carer 
strain, anxiety and depression. These are defined as a rela-
tive or friend providing help with activities of daily living 
or physical care, at least 4 days a week. Carer participants 
will provide informed consent but will not receive any 
trial intervention, so will not undergo eligibility screening 
or randomisation.
Trial treatment/interventions
We plan to compare an enhanced rehabilitation interven-
tion with usual rehabilitation care.
Usual rehabilitation care
Usual care consists of a multidisciplinary rehabilitation 
delivered by the acute hospital, community hospital and 
community services depending on patients’ individual 
needs at different times during their recovery and on the 
availability and accessibility of services in different areas. 
The multidisciplinary team delivering care and rehabili-
tation may include: orthopaedic surgeons, orthogeriatri-
cians, nurses, physiotherapists, occupational therapists, 
dieticians, pharmacists, general practitioners (GPs) and 
social workers. The settings for care include acute ortho-
paedic or orthogeriatric wards, rehabilitation units in 
community hospitals, rehabilitation beds in care homes, 
the patient’s own home and care home settings, all deliv-
ered by a variety of community teams in both health 
and social care services. There will be no restrictions on 
concomitant medications or treatments.
Enhanced rehabilitation
The main aim of the intervention is to enhance usual 
rehabilitation by increasing patients’ self- efficacy25 and 
increasing the amount and quality of patients’ practice of 
physical exercise and activities of daily living to improve 
functional outcomes at follow- up. Self- efficacy will be 
enhanced by means of a patient- held information work-
book and a goal setting diary. The workbook will include:
 ► Information about what has happened to them and 
what to expect from their recovery.
 ► Information about NHS, council and voluntary sector 
services including falls’ prevention programmes.
 ► How to manage their recovery, set goals and monitor 
progress of their rehabilitation; reduce fear of falling.
In addition to whatever community- based rehabili-
tation is provided as part of usual care, we will provide 
up to six additional therapy sessions, once patients are 
discharged home. These can be delivered by physiothera-
pists, occupational therapists or their assistants, who have 
been trained to deliver these extra sessions alongside 
the workbook, using the diary to set goals and monitor 
progress. The therapists will tailor these extra sessions, so 
that the total number of sessions used, the time scale for 
their delivery and the sessions’ content will vary between 
patients according to need but may include the practice of 
specific exercises and activities of daily living. Throughout 
the running of this trial, therapists will receive on- going 
support via emails, newsletters and refresher events.
Outcomes
Patient participants will complete outcome measures at 
baseline, 17 and 52 weeks administered by a research 
assistant blinded to participant allocation. Follow- up 
assessments will be completed within participants’ homes 
(tables 1 and 2). The primary outcome will be the differ-
ence in NEADL scale26 27 at 52- week follow- up, between 
the usual rehabilitation arm and the enhanced rehabili-
tation arm. At baseline, the patient will be asked to recall 
the 4 weeks prior to hip fracture and not 4 weeks prior 
to completing this questionnaire. Secondary outcomes 
will include the Hospital Anxiety and Depression 
Scale (HADS),28 economic measures will be EuroQol, 
EQ- 5D- 3L29 and Client Service Receipt Inventory.30 A 
reduced version of this will be used at baseline to reduce 
participant burden as they recover from hip fracture 
surgery. Potential mediators of outcome will include a 
Visual Analogue Scale (VAS) for hip pain intensity,31 Falls 
Efficacy Scale—International (self- efficacy)32 33 and Visual 
Analogue Scale—Fear of Falling (VASFoF).34
The research assistant will assess patient participants’ 
cognitive function at baseline, 17 and 52 weeks using the 
Abbreviated Mental Test Score.35 The research assistant 
will measure physical function at baseline, 17 and 52 
weeks using the grip strength test36–38 and using the Short 
Physical Performance Battery39 40 at 17 and 52 weeks.
Carer participants will complete the Caregiver Strain 
Index41 and the HADS28 at baseline, 17 and 52 weeks.
Qualitative interviews will take place with patients and 
carers after 17 weeks. These will gather data on trial 
participation and intervention design (see the Process 
evaluation below).
Routinely collected demographic, clinical and recruit-
ment data will include the numbers of patients who are 
eligible, willing to be randomised, withdraw after rando-
misation, complete outcome measurements, also reasons 
for non- completion, age, gender, hip fracture type, 
surgery type, comorbid conditions, place of residence 
prior to admission and place of discharge.
Sample size calculation
The phase II feasibility study results23 informed the 
sample size calculation. The adjusted mean difference 
in the primary outcome measure (NEADL) between the 
intervention and control group in the feasibility trial 
was 3.0. Work completed by Wu et al27 has suggested 
that the minimum clinically significant difference is 2.4; 
this has been used within the sample size calculation 
for this phase III RCT. A two- point score in the NEADL 
scale would equate to an improvement in function from 
being independent around the home to being able to use 
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public transport or get in and out of a car. The adjusted 
mean difference between the groups in NEADL in the 
randomised feasibility study had an SD of 5.8. In this 
multisite phase III RCT, a more diverse sample would be 
expected, so a larger SD would be expected. Parker et al42 
used NEADL in a rehabilitation RCT and found an SD of 
10. Based on the analysis of covariance (ANCOVA) with 
alpha of 5% and 90% power to detect a difference of 2.4 
(SD=10, R2 of covariate=0.52), 352 patient participants 
would be required to complete the trial over both treat-
ment groups. When considering the 79% retention rate 
in the feasibility study,23 the trial would need to recruit 
446 patient participants.
Recruitment and randomisation
Screening and consent—patient participants
Patients with proximal femoral fracture will be identified 
and screened for eligibility, including mental capacity, by 
clinical staff on orthopaedic or rehabilitation wards. If the 
patients are eligible, and interested in the trial, the trial 
team researchers would then recruit patients following 
the trial’s informed consent process. Assessment of 
eligibility may occur over an extended period, if, for 
example, the patient is experiencing temporary delirium 
postsurgery. If, during this period, patients are trans-
ferred to rehabilitation wards, community hospitals or 
discharged home, then assessment will continue in these 
Table 1 Outcome measures
Patient completed measures—primary Description Range
Nottingham Extended Activities of Daily Living scale26 27 Activities of daily living (mobility, kitchen, domestic, leisure) 
with higher score indicating greater independence
(0–66)
Patient completed measures—secondary
Hospital Anxiety and Depression Scale (HADS)28 Anxiety and depression in patients with physical health 
problems. Two subscales (0–21) with higher score indicate 
greater anxiety or depression
(0–21)
Patient completed economic measures   
EuroQol EQ- 5D- 3L29 Health utility index with five dimensions (mobility, self- 
care, usual activities, pain/discomfort, anxiety/depression) 
and three levels to give health states converted to a utility 
weight. Also Visual Analogue Scale (VAS) for health state 
today
Health utility 
weight from 
0 (death) to 
1.0 (perfect 
health) also 
with negative 
values
VAS (0–100)
Client Service Receipt Inventory
30
Use of health and social care services According to 
activity
Patient completed process measures (potential mediators of outcomes)
Visual Analogue Scale (VAS) for hip pain intensity31 VAS of current hip pain intensity (0–10 cm)
Falls Efficacy Scale— International (self- efficacy)32 33 How concerned a patient is about falling when performing 
16 activities of daily living both inside and outside of 
the home, rated from 1 (not at all concerned) to 4 (very 
concerned)
(16–64)
VAS- Fear of Falling34 VAS with higher scores indicating greater fear of falling (0–10 cm)
Assessment of cognitive function   
Abbreviated Mental Test Score35 36 Detecting and monitoring cognitive impairment. 10 items 
with lower scores indicating worse cognitive function
(0–10)
Objective measures of physical function
Grip strength37 Hand dynamometer According to 
metre reading
Short Physical Performance Battery40 41 Physical function tests assessing lower limb function in 
terms of balance, gait, strength and endurance. Higher 
score indicates greater function
(0–12)
Carer completed measure—secondary outcome
Caregiver Strain Index42 13 items in the domains: employment, financial, physical, 
social and time. Positive responses to seven or more items 
indicate a greater level of strain
(0–13)
HADS28 Anxiety and depression in carers. Two subscales (0–21) 
with higher score indicate greater anxiety or depression
(0–21)
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Table 2 Fracturein the Elderly Multidisciplinary Rehabilitation—phase III (FEMuR III) protocol schedule of forms and 
procedures
Procedures Screening Baseline/randomisation*
Trial 
intervention†
17 weeks 
postrandomisation 
follow- up
Qualitative 
interviews
52 weeks 
postrandomisation 
follow- up
Eligibility screening 
and consent
            
Assessment of 
eligibility criteria
X           
  Written and 
informed consent 
(patient/carer)
X           
Confirm consent   X X X X X
Randomisation   X         
Discharge data   X         
Outcome 
measurement— 
patient
            
  Nottingham 
Extended 
Activities of Daily 
Living
  X   X   X
  Hospital Anxiety 
and Depression 
Scale (HADS)
  X   X   X
  Abbreviated 
Mental Test Score
  X   X   X
  Visual Analogue 
Scale (VAS) hip 
pain intensity
  X   X   X
  Falls Efficacy 
Scale—
International
  X   X   X
  Visual Analogue 
Score—Fear of 
Falling
  X   X   X
  EuroQol-5D- 3L   X   X   X
  Client Service 
Receipt Inventory
  X   X   X
  Grip strength   X   X   X
  Short Physical 
Performance 
Battery
      X   X
Outcome 
measurement— 
carer
            
  Caregiver Strain 
Index
  X   X   X
  HADS   X   X   X
Trial intervention†     X       
Qualitative interviews             
Re- affirm consent 
verbally specifically 
for qualitative phone 
interview. (patient/
carer)
        X   
Continued
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alternative locations. These assessments will be recorded 
in a screening log, including any reasons for ineligibility.
Informed consent—carer participants
For the purpose of this RCT, carers are defined as either a 
relative or friend caring for a hip fracture patient, helping 
them with activities of daily living or physical care on at 
least 4 days a week. They will be identified and recruited 
following the trial’s informed consent process. Copies of 
the participant information sheets and informed consent 
forms are found in online supplemental appendix 1.
Randomisation procedures
Patient participants who provide informed consent will 
complete baseline outcome measurements prior to 
randomisation. Randomisation will take place no later 
than 6 weeks after hip fracture repair surgery. The rando-
misation will have an allocation ratio of 1:1 within each 
stratum and across the trial. Randomisation will use a 
minimisation programme with a built- in random element 
using factors that will not be made known to individuals 
in charge of recruitment to minimise any potential for 
predicting allocation. Randomisation will be completed 
by secure web access to the remote randomisation site 
at the clinical trial unit. The therapists delivering the 
enhanced rehabilitation intervention will receive an auto-
mated email when a participant has been allocated to the 
intervention group.
Blinding
This is a pragmatic trial comparing two rehabilitation 
interventions. It will therefore not be possible to blind 
participants or their clinicians to treatment group allo-
cation. The research assistants will collect outcome 
measurements blind to treatment allocation. They will 
not be informed to which group the patient participants 
have been allocated and will not be present at any of the 
therapy sessions. Before any home visits for follow- up 
assessments, they will ask participants not to reveal their 
treatment allocation. After the final follow- up assessment, 
they will complete a perception of allocation form, in 
order to monitor the level of blinding achieved for these 
researchers. Data analysis will be performed blind to 
treatment allocation.
Internal pilot
An internal pilot- assessed site recruitment and participant 
recruitment and retention rates for the 6 months after the 
first site were open to recruitment from September 2019 
to February 2020.
Progression criteria
 ► Number of sites open: seven or more (go); five to six 
(amend); four or fewer (stop).
 ► Open site recruitment rate per month: two or more 
(go); one to two (amend); less than 1 (stop).
 ► Retention rate: 69% or higher (go); 50%–68% 
(amend); 49% or fewer (stop).
Statistical analysis
Final analysis will take place once all participants have 
been followed up for 52 weeks, and the database has 
been locked. Analyses will be by ‘intention to treat’ for 
the primary and secondary outcomes on all randomised 
participants, in the group to which they were allocated 
and for whom the outcomes of interest have been 
observed or measured.
Baseline
Demographic and baseline characteristics will be 
summarised separately using descriptive statistics for each 
randomised group to allow clinical assessment of whether 
balance was achieved between randomised groups. No 
statistical testing of differences between groups will be 
performed.
Analysis of effectiveness
Primary and secondary outcomes at baseline, 17 weeks’ 
and 52 weeks’ follow- up will be summarised for each 
treatment group using descriptive statistics at each time 
point. If normally distributed, the difference between 
group means (with 95% CIs) will be reported from the 
Procedures Screening Baseline/randomisation*
Trial 
intervention†
17 weeks 
postrandomisation 
follow- up
Qualitative 
interviews
52 weeks 
postrandomisation 
follow- up
Qualitative telephone 
interview
        X   
Safety event 
reporting
            
Monitoring of 
adverse events
    X X X X
Monitoring of serious 
adverse events
    X X X X
Participant follow- up visits should take place at 17 (±2 weeks) and 52 (±2 weeks) weeks postrandomisation.
*Randomisation and baseline should take place no later than 6 weeks after hip fracture repair surgery.
†If randomised to intervention arm.
Table 2 Continued
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ANCOVA adjusted for baseline score and stratification 
factors.
Missing data and withdrawals
Predictors of missing data will be investigated using 
regression models (including type of surgery, age, living 
arrangements and comorbidities) and any significant 
predictors will be considered for inclusion in the models. 
In addition, given the two assessment points at 17 and 
52 weeks, we will carry out a sensitivity analysis using a 
joint modelling approach to check whether there is any 
difference in outcome (here the longitudinal outcome 
rather than the outcome at 17 weeks or 52 weeks alone) 
between the randomised arms adjusted for dropouts or 
missing values.
Instrumental variable regression
The impact of engagement with the intervention will 
be assessed using instrumental variable (IV) regression, 
using the number of face- to- face direct rehabilitation 
sessions over 52 weeks’ follow- up as a continuous measure 
of engagement. Additional exploratory IV regression 
analyses will use in turn: the total number of rehabili-
tation sessions (face- to- face plus telephone), total time 
(in minutes) spent in face- to- face direct rehabilitation 
sessions and total time (in minutes) spent in all rehabili-
tation sessions (ie, face- to- face and telephone). The suit-
ability of using randomisation as the instrument in these 
IV regression models will be assessed using tests of exoge-
neity, redundancy and under/weak identification.
Mediation analyses
The hypothesised mechanism of change for the enhanced 
rehabilitation intervention is that participants’ primary 
outcome (activities of daily living) is mediated by self- 
efficacy, hip pain, cognitive function, fear of falling and 
physical function. If the enhanced rehabilitation interven-
tion has a significant effect on primary outcome (p<0.05) 
for enhanced rehabilitation in ANCOVA, causal media-
tion analysis will be used to determine whether each of 
these potential mediators predict change in NEADL at 
52 weeks. Initial assessments will determine whether the 
randomised intervention affects each putative mediator 
in turn. For those putative mediators that are significantly 
(p<0.1) affected by the randomised intervention, medi-
ation analysis will be carried out adjusting for baseline 
covariates that predict both the mediator and NEADL, 
potentially including type of surgery, age, living arrange-
ments (alone/with others) and comorbidities. Sensitivity 
analyses will assess the potential impact of unmeasured 
confounding between the mediator and NEADL.
Economic analysis
The enhanced rehabilitation programme will be fully 
costed using unit costs from a public sector multiagency 
perspective. Unit costs will be obtained from national 
sources of reference costs43 44 and applied to information 
received from pilot questionnaires, namely, salary band 
of therapists, time spent with the patient conducting 
rehabilitation, costs of travel and costs of any additional 
equipment. Costs of health and social care services used 
by the participants will also be costed using national 
sources of reference costs. The costs of service use and 
the cost of the intervention will be added together for use 
in a cost- effectiveness analysis.
The EQ- 5D (3L) will be used to calculate Quality 
Adjusted Life Years (QALYs) over the 52- week trial 
period, using the area under the curve method.45 46 A 
cost- utility analysis will be conducted to calculate a cost 
per QALY of the enhanced rehabilitation intervention. 
This cost per QALY generated will be compared with the 
NICE threshold range of £30 000 per QALY.47 We will 
bootstrap differences in costs and outcomes (EQ- 5D- 3L) 
between the two groups, producing a 95% CI around 
these differences.
Process evaluation
The process evaluation will aim to identify and explain all 
mechanisms and processes (ie, the intervention theory) 
that enabled or acted as a barrier to the implementa-
tion of the enhanced rehabilitation intervention. The 
process evaluation will help build a picture of how the 
intervention was carried out in reality and what factors 
shaped it. By carrying out a process evaluation, it will be 
possible to identify if observed impacts are solely due 
to the enhanced rehabilitation programme, or if these 
impacts are a result of a number of external and internal 
variables that are closely linked to the environment and 
the context in which the intervention takes place.48–51
The specific objectives will be to:
 ► Refine the programme theory from the previous 
realist review that was used to develop the interven-
tion.21 This programme theory will explain how the 
researchers envisage the intervention to work, to 
reach its expected outcomes.
 ► Investigate therapists’ expectations and experience 
of implementation, their previous experience and 
training and their learning throughout the conduct 
of the trial.
 ► Investigate the mechanisms driving and shaping the 
tailoring of the enhanced rehabilitation intervention 
to individual patients.
 ► Investigate trial participants’ (patients and carers) 
experiences and views about their involvement in the 
trial as well as their experience of care in either arm 
of the trial.
 ► Map and synthesise all data collected in order to test 
the refined programme theory and explain the trial 
findings.
Process evaluation data collection
Semistructured telephone interviews will be conducted 
with:
 ► A purposive sample of 60 patient participants in each 
of the two trial arms and up to 30 of their carers. 
Patients will be purposively sampled to ensure diver-
sity based on age, functional impairment (using 
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baseline NEADL scores) and the presence or absence 
of a family carer. Interviews will take place after the 
17- week assessment and will be audio recorded.
 ► The therapists delivering the enhanced rehabilita-
tion programme, which will explore implementation 
from the therapists’ perspectives. Interviews will be 
conducted midway through their involvement in the 
trial, and at the end, in order to investigate learning 
over time.
Data on intervention delivery and adherence
 ► Therapists will record key reflections on ‘critical inci-
dent reports’.
 ► The visiting therapist will record the length and 
content of each extra rehabilitation therapy session 
on a case report form.
 ► All patient participants will be given a therapy session 
record, where visiting therapists will record the 
number, length and content of usual rehabilitation 
care. Whenever possible, routinely collected elec-
tronic data that therapists complete on their Therapy 
Manager system, or its equivalent, will be collected.
 ► An online questionnaire will be emailed to partici-
pating therapists in order to capture therapists’ rele-
vant training, previous experience and familiarity with 
the trial intervention.
Qualitative data will be analysed following a thematic 
analysis approach52 that will be guided by the proposed 
programme theory. Quantitative data (record forms 
and online questionnaires) will be analysed using 
descriptive statistics, which will allow the exploration 
of frequency of responses. All data sets will be synthe-
sised in order to describe the complex nature of the 
enhanced rehabilitation intervention.
Patient and public involvement
There has been patient and public involvement (PPI) 
at all stages including refining the research question, 
choosing outcomes relevant to patients, commenting 
on the burden of the intervention and of trial partici-
pation. A PPI coinvestigator will continue to contribute 
to the trial management group, including comments on 
patient- facing materials and the dissemination plan.
Ethics and dissemination
NHS research ethics approval was obtained from North 
East—Tyne & Wear South Research Ethics Committee, 
reference 18/NE/0300. The current protocol is V.4.0 
(11 December 2019). A Trial Steering Committee is 
providing overall supervision and an Independent 
Data Safety and Monitoring Committee is responsible 
for reviewing and assessing recruitment, interim moni-
toring of safety and effectiveness, trial conduct and 
external data.
All safety events will be recorded by researchers when 
they are made aware of the event by the patient, carer, 
the treating clinicians or therapists. Adverse event 
reports and serious adverse events (SAEs) not related 
to the intervention will be entered on to the remote 
data entry system. Each SAE will be assessed by the rele-
vant principal investigator (PI) to determine whether 
it is related to the intervention. A related SAE will be 
assessed by the CI to determine whether it is expected. 
If the SAE is related and unexpected, it will be reported 
to the Research Ethics Committee and sponsor in an 
expedited manner.
Reporting of the trial will be consistent with the Consol-
idated Standards of Reporting Trials 2010 Statement 
(patient- reported outcomes and non- pharmacological 
interventions).53 We will submit the final report to 
a peer- reviewed academic journal, according to our 
publication strategy and authorship policy. Research 
data will be available for secondary analysis on reason-
able request.
Trial status
At the time of submission, this trial had been open in nine 
sites and had recruited 96 patients and 10 carers, with 
a recruitment rate of two patient participants per site 
per month and a retention rate of 83%, which fulfilled 
the progression criteria of the internal pilot. However, 
recruitment to the trial is currently suspended because 
of the COVID-19 pandemic. Wherever possible, partici-
pants already recruited into the trial will complete their 
follow- up assessments over the telephone or by post, 
extra rehabilitation sessions will be delivered over the 
telephone. When trial recruitment resumes, updated 
recruitment information will be found on the website 
http:// femur3study. co. uk/
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